CellCentric company

CellCentric’s primary programme targets a deubiquitinase (DUB) enzyme which is strongly associated with prostate cancer, a leading cause of mortality among men. The target modulates the androgen receptor pathway and can potentially combat the multiple resistance mechanisms seen with recently approved prostate cancer drugs such Xtandi and Zytiga.
The programme also has potential clinical utility in non-small cell lung, breast and colon cancer.
Technology: P4 Medicine
Industry: Regenerative Medicine
Headquarters: Cambridge, Cambridgeshire, United Kingdom
Founded Date: 6-25
Employees Number: Undisclosed
Funding Status: N/A
Investors Number: 9
Total Funding: $42.6M
Estimated Revenue: $10M to $50M
Last Funding Type: Venture - Series Unknown

Visit Website
Register and Claim Ownership